Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
0.5380
-0.0010 (-0.19%)
At close: May 12, 2025, 4:00 PM
0.5200
-0.0180 (-3.35%)
After-hours: May 12, 2025, 6:50 PM EDT
Intensity Therapeutics Employees
As of December 31, 2024, Intensity Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,324,000
Market Cap
8.17M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | 0 | - |
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INTS News
- 6 days ago - Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France - PRNewsWire
- 17 days ago - Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PRNewsWire
- 2 months ago - Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review - PRNewsWire
- 4 months ago - Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 - PRNewsWire
- 5 months ago - Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS) - PRNewsWire
- 6 months ago - Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - PRNewsWire
- 6 months ago - Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS) - PRNewsWire